4 results
Our study tries to identify the ideal sclerosant dosage for the ClariVein® system in order to occlude the GSV permanently. By choosing the lowest dose with the same anatomical success rate, we achieve a safe treatment which also gives us the…
Objective: To evaluate the anatomical success of MOCA versus RFA in treatment of symptomatic insufficient SSV.
Primary objective 1) To evaluate the usability of the total viQtor solution applied and used 24/7 in clinical practice.This includes the ease of use and/or usability of:the wearable, charger and armband by the primary participants/usersthe *care…
The primary endpoint is the evaluation of the safety and toxicity of TIL with nivolumab and, thereafter, the safety and toxicity of the combination of PEG-IFNa, nivolumab plus TIL. Safety and toxicity will be evaluated according to CTCAE 4.0…